|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
More than 90% of small cell lung cancers (SCLCs) harbor loss-of-function mutations in the tumor suppressor gene <i>RB1</i> The canonical function of the <i>RB1</i> gene product, pRB, is to repress the E2F transcription factor family, but pRB also functions to regulate cellular differentiation in part through its binding to the histone demethylase KDM5A (also known as RBP2 or JARID1A).
|
31727771 |
2019 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In conclusion, CRABP-II and FABP5 expression patterns are neither related to the tumor grades nor correlated with RA sensitivity.
|
25797252 |
2015 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition, RBP2 loss suppresses tumor formation in MMTV-neu transgenic mice.
|
24582965 |
2014 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Therefore, RBP2 may link chronic inflammation to tumor development and its inhibition may have potential therapeutic advantages.
|
25015565 |
2014 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Neither LSD1 nor RBP2 expression was significantly associated with age, gender, stage status, tumor size, and lymph node metastases (p>0.05).
|
24068396 |
2013 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Preclinical data suggest that inhibition of RBP2 or PLU-1 would suppress tumor growth.
|
20973793 |
2010 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Several genes have been newly associated with gastric carcinogenesis, both through oncogenic activation (MYC, SEMA5A, BCL2L12, RBP2 and BUBR1) and tumor suppressor gene inactivation mechanisms (KLF6, RELN, PTCH1A, CLDN11, and SFRP5).
|
21054651 |
2010 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The observations reveal that CRABP-II plays a critical role in sensitizing tumors to the growth-suppressive activities of RA in vivo.
|
12907615 |
2003 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The value of RBP2 as a therapeutic target in cancer, however, hinges on whether loss of RBP2 could block the growth of established tumors as opposed to simply delaying their onset.
|
29610306 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
RBP2 activates ER-IGF1R-ErbB signaling cascade in multiple ways to induce tamoxifen resistance, suggesting that RBP2 is a potential therapeutic target for ER-driven cancer.
|
29028222 |
2018 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
|
29028222 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Lysine demethylase 5A (KDM5A/RBP2/JARID1A) is a histone lysine demethylase that is overexpressed in several human cancers including lung, gastric, breast and liver cancers.
|
27224921 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further data indicate that knockdown of endogenous RBP2 dominantly inhibits gastric cancer (GC) development both in vitro and in vivo.
|
25015565 |
2014 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
|
24716659 |
2014 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
By using both human breast cancer cells and genetically engineered mice, we demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple in vivo models.
|
24582965 |
2014 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further data indicate that knockdown of endogenous RBP2 dominantly inhibits gastric cancer (GC) development both in vitro and in vivo.
|
25015565 |
2014 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
|
24716659 |
2014 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Cancerous and matched normal gastric specimens from 42 patients with gastric cancer were analyzed for RBP2 expression using quantitative real-time polymerase chain reaction and immunohistochemistry.
|
19850045 |
2010 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Cancerous and matched normal gastric specimens from 42 patients with gastric cancer were analyzed for RBP2 expression using quantitative real-time polymerase chain reaction and immunohistochemistry.
|
19850045 |
2010 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Stable expression of CRABP-II in mammary carcinoma SC115 cells enabled activation of RAR, considerably sensitized the cells to RA-induced growth inhibition, and dramatically suppressed their tumorigenicity in immunodeficient mice.
|
12907615 |
2003 |
|
Blast Phase
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that the under-expression of RBP2 promotes blast crisis transition by activating an RBP2/PTEN/BCR-ABL cascade.
|
31374292 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
|
29028222 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
RBP2 activates ER-IGF1R-ErbB signaling cascade in multiple ways to induce tamoxifen resistance, suggesting that RBP2 is a potential therapeutic target for ER-driven cancer.
|
29028222 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
The value of RBP2 as a therapeutic target in cancer, however, hinges on whether loss of RBP2 could block the growth of established tumors as opposed to simply delaying their onset.
|
29610306 |
2018 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
RBP2 is expected to become a new potential therapeutic target for HCC.
|
28582381 |
2017 |